Greenwich LifeSciences (GLSI) Change in Account Payables (2019 - 2026)

Greenwich LifeSciences (GLSI) has 6 years of Change in Account Payables data on file, last reported at $2.1 million in Q4 2025.

• Quarterly Change in Account Payables rose 5.52% year-over-year to $2.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.1 million (down 18.66% YoY) and the FY2025 annual result came in at $2.1 million, down 18.66% from the prior year.
• Change in Account Payables climbed to $2.1 million in Q4 2025, from -$187590.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $2.1 million in Q4 2025 to a low of -$560472.0 in Q3 2024.
• A 4-year average of $311330.3 and a median of -$69561.0 in 2023 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 7880.28% in 2024, down 705.73% in 2024.
• Tracing GLSI's Change in Account Payables over 4 years: stood at -$75000.0 in 2021, then jumped by 133.89% to $25415.0 in 2023, then soared by 7880.28% to $2.0 million in 2024, then increased by 5.52% to $2.1 million in 2025.
• The last three Change in Account Payables figures came in at $2.1 million (Q4 2025), -$187590.0 (Q3 2025), and $248595.0 (Q2 2025), per Business Quant data.